ADMA vs CSL: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: ADMA is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ADMA and CSL share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ADMA and CSL exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

ADMA Biologics is an end-to-end biopharmaceutical company focused on plasma-derived therapies. It develops, manufactures, and markets immunoglobulin (IG) products and operates its own plasma-collection centers, giving it control over part of the supply chain that feeds its manufacturing. Its FDA-approved products include Asceniv, an intravenous immune globulin used to treat primary immunodeficiency, Bivigam, a standard intravenous immune globulin, and Nabi-HB for hepatitis B exposure. Asceniv is the company's differentiated, higher-value product and has been the main growth driver, while Bivigam competes in the more crowded standard-IG market.

Full ADMA guide

Carlisle Companies Incorporated (NYSE: CSL) is a diversified manufacturer that, after years of portfolio reshaping, has become a focused supplier of building-envelope products that make commercial and residential buildings more energy efficient. It operates through two segments: Carlisle Construction Materials (CCM), which makes single-ply roofing membranes (EPDM rubber, TPO, and PVC), polyiso insulation, and metal roofing and wall systems, and Carlisle Weatherproofing Technologies (CWT), which makes waterproofing, air and vapor barriers, sealants, spray polyurethane foam, coatings, and related moisture-protection products. The company earns most of its revenue from commercial construction, and within that, a large share comes from re-roofing (replacing aging roofs), which is more stable than new construction because roofs wear out on a predictable cycle regardless of the economy.

Full CSL guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ADMA drivers: Asceniv, the specialty growth driver; Integrated plasma-collection model.
• CSL drivers: Commercial re-roofing replacement cycle; Margin expansion and pure-play focus.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant near-term risk is competition and pricing pressure in the standard immunoglobulin market, which drove a 54% drop in Bivigam revenue and led ADMA in 2026 to cut full-year guidance, reduce its net-income outlook, and withdraw long-term targets, citing rapidly evolving competitive dynamics. For CSL, carlisle's end markets are cyclical: commercial and residential construction activity is sensitive to interest rates, credit availability, and the broader economy, and a downturn in construction spending would pressure volumes.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ADMA if you believe its drivers more; CSL if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ADMA and CSL guides.

ADMA. Figures are approximate and tied to the asOf date; verify live numbers before acting. ADMA is profitable, so an earnings multiple is meaningful, but the 2026 guidance cut and withdrawn long-term targets make forward estimates less certain than before, so investors should weigh the durability of Asceniv growth against standard-IG competition rather than rely on a single multiple. The mix shift toward specialty product matters more here than headline revenue, which stayed flat.

CSL. Carlisle trades around a low-20s trailing P/E, roughly in line with its own long-term historical median and typical for a high-margin, cash-generative industrial. Because a large part of its earnings power comes from resilient re-roofing demand and steady margin expansion, investors tend to focus on adjusted EBITDA margin, free cash flow, and the pace of buybacks rather than raw revenue growth, which can be lumpy with weather and construction cycles. The Q1 2026 revenue dip was driven largely by poor winter weather that limited roofing installation, while margins still expanded and management reaffirmed full-year guidance for low-single-digit revenue growth.

Headline figures (approximate, Jul 2026): ADMA shows revenue (q1 2026) ~$114.5 million, roughly flat year over year, eps (q1 2026) ~$0.19, up about 73% year over year, product mix trend Asceniv revenue up ~28%; Bivigam down ~54%, 2026 revenue guidance cut to ~$530 to $560 million (from a prior view above $635 million); CSL shows revenue (ttm) ~$5.0 billion, q1 2026 revenue ~$1.05 billion (down ~4% year over year), q1 2026 adjusted eps ~$3.63 (up ~1% year over year), q1 2026 adjusted ebitda margin ~22.3% (up ~50 bps).

ADMA and CSL are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ADMA and CSL exposure against your real portfolio. It is not an investment adviser.